Literature DB >> 3201394

Immunoblotting studies of the molecular forms of protein C in plasma.

M J Heeb1, H P Schwarz, T White, B Lämmle, M Berrettini, J H Griffin.   

Abstract

Anti-plasma protein C monoclonal antibodies were prepared and characterized, and quantitative immunoblotting techniques were developed to determine the molecular forms of protein C in whole plasma. Two antibodies reacted with the heavy chain of protein C, four reacted with the light chain, and two reacted only with nonreduced protein C. A doublet of protein C (MW = 63-66K) was seen on nonreduced immunoblots of normal plasma and 30 heterozygous protein C deficient plasmas (2-77% protein C antigen). In reduced plasma, approximately 75% of protein C presented as doublet heavy chains (MW = 39-42K) and doublet light chains (MW = 22-25K), and approximately 25% was single chain (MW = 64K). The immunoblotting technique was quantitative, specific, sensitive, and correlated with electroimmunoassay results. It also provided visual qualitative information not obtainable with other methods of quantitation.

Mesh:

Substances:

Year:  1988        PMID: 3201394     DOI: 10.1016/0049-3848(88)90038-2

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  11 in total

1.  Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease-activated receptor-1 and endothelial cell protein C receptor.

Authors:  Laurent O Mosnier; John H Griffin
Journal:  Biochem J       Date:  2003-07-01       Impact factor: 3.857

2.  An engineered factor Va prevents bleeding induced by direct-acting oral anticoagulants by different mechanisms.

Authors:  Annette von Drygalski; Vikas Bhat; Andrew J Gale; Patricia M Averell; Thomas J Cramer; Darlene J Elias; John H Griffin; Laurent O Mosnier
Journal:  Blood Adv       Date:  2020-08-11

3.  Models of the serine protease domain of the human antithrombotic plasma factor activated protein C and its zymogen.

Authors:  C L Fisher; J S Greengard; J H Griffin
Journal:  Protein Sci       Date:  1994-04       Impact factor: 6.725

4.  Phenotypic and genotypic stability of multiple lines of transgenic pigs expressing recombinant human protein C.

Authors:  K E Van Cott; H Lubon; C G Russell; S P Butler; F C Gwazdauskas; J Knight; W N Drohan; W H Velander
Journal:  Transgenic Res       Date:  1997-05       Impact factor: 2.788

5.  α2-Macroglobulin Is a Significant In Vivo Inhibitor of Activated Protein C and Low APC:α2M Levels Are Associated with Venous Thromboembolism.

Authors:  Laura Martos; Luis Andrés Ramón; Julia Oto; Álvaro Fernández-Pardo; Santiago Bonanad; Ana Rosa Cid; Andras Gruber; John H Griffin; Francisco España; Silvia Navarro; Pilar Medina
Journal:  Thromb Haemost       Date:  2018-02-15       Impact factor: 5.249

6.  Nonenzymatic anticoagulant activity of the mutant serine protease Ser360Ala-activated protein C mediated by factor Va.

Authors:  A J Gale; X Sun; M J Heeb; J H Griffin
Journal:  Protein Sci       Date:  1997-01       Impact factor: 6.725

7.  Activated protein C up-regulates procoagulant tissue factor activity on endothelial cells by shedding the TFPI Kunitz 1 domain.

Authors:  Reto A Schuepbach; Kara Velez; Matthias Riewald
Journal:  Blood       Date:  2011-04-07       Impact factor: 22.113

8.  Species-specific anticoagulant and mitogenic activities of murine protein S.

Authors:  José A Fernández; Mary J Heeb; Xiao Xu; Itender Singh; Berislav V Zlokovic; John H Griffin
Journal:  Haematologica       Date:  2009-10-08       Impact factor: 9.941

9.  Protein S binds to and inhibits factor Xa.

Authors:  M J Heeb; J Rosing; H M Bakker; J A Fernandez; G Tans; J H Griffin
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-29       Impact factor: 11.205

10.  Protein C inhibitor is expressed in tubular cells of human kidney.

Authors:  K P Radtke; J A Fernández; J S Greengard; W W Tang; C B Wilson; D J Loskutoff; I Scharrer; J H Griffin
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.